LEXICON PHARMACEUTICALS, INC. Total Contract Liability
LEXICON PHARMACEUTICALS, INC. (LXRX) had Total Contract Liability of $45.00 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-05-14
- 2025-03-31: Contract with Customer, Liability $45.00M.
- 2024-12-31: Contract with Customer, Liability $0.00.
| Period end | Contract with Customer, Liability |
|---|---|
| 2025-03-31 | $45.00M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $0.00 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |